147 related articles for article (PubMed ID: 37429857)
1. Cell cycle arrest and p53 prevent ON-target megabase-scale rearrangements induced by CRISPR-Cas9.
Cullot G; Boutin J; Fayet S; Prat F; Rosier J; Cappellen D; Lamrissi I; Pennamen P; Bouron J; Amintas S; Thibault C; Moranvillier I; Laharanne E; Merlio JP; Guyonnet-Duperat V; Blouin JM; Richard E; Dabernat S; Moreau-Gaudry F; Bedel A
Nat Commun; 2023 Jul; 14(1):4072. PubMed ID: 37429857
[TBL] [Abstract][Full Text] [Related]
2. CRISPR-Cas9 globin editing can induce megabase-scale copy-neutral losses of heterozygosity in hematopoietic cells.
Boutin J; Rosier J; Cappellen D; Prat F; Toutain J; Pennamen P; Bouron J; Rooryck C; Merlio JP; Lamrissi-Garcia I; Cullot G; Amintas S; Guyonnet-Duperat V; Ged C; Blouin JM; Richard E; Dabernat S; Moreau-Gaudry F; Bedel A
Nat Commun; 2021 Aug; 12(1):4922. PubMed ID: 34389729
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9 treatment causes extended TP53-dependent cell cycle arrest in human cells.
Geisinger JM; Stearns T
Nucleic Acids Res; 2020 Sep; 48(16):9067-9081. PubMed ID: 32687165
[TBL] [Abstract][Full Text] [Related]
4. CRISPR-Cas9 Editing Induces Loss of Heterozygosity in the Pathogenic Yeast Candida parapsilosis.
Lombardi L; Bergin SA; Ryan A; Zuniga-Soto E; Butler G
mSphere; 2022 Dec; 7(6):e0039322. PubMed ID: 36416551
[TBL] [Abstract][Full Text] [Related]
5. No apparent p53 activation in CRISPR-engineered gene-edited rabbits.
Zhang T; Li J; Wang T; Zhao F; Sui T
J Cell Mol Med; 2021 Nov; 25(21):10313-10317. PubMed ID: 34609046
[TBL] [Abstract][Full Text] [Related]
6. ON-Target Adverse Events of CRISPR-Cas9 Nuclease: More Chaotic than Expected.
Boutin J; Cappellen D; Rosier J; Amintas S; Dabernat S; Bedel A; Moreau-Gaudry F
CRISPR J; 2022 Feb; 5(1):19-30. PubMed ID: 35099280
[TBL] [Abstract][Full Text] [Related]
7. CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response.
Haapaniemi E; Botla S; Persson J; Schmierer B; Taipale J
Nat Med; 2018 Jul; 24(7):927-930. PubMed ID: 29892067
[TBL] [Abstract][Full Text] [Related]
8. Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing.
Leibowitz ML; Papathanasiou S; Doerfler PA; Blaine LJ; Sun L; Yao Y; Zhang CZ; Weiss MJ; Pellman D
Nat Genet; 2021 Jun; 53(6):895-905. PubMed ID: 33846636
[TBL] [Abstract][Full Text] [Related]
9. Large-scale genome editing based on high-capacity adenovectors and CRISPR-Cas9 nucleases rescues full-length dystrophin synthesis in DMD muscle cells.
Tasca F; Brescia M; Wang Q; Liu J; Janssen JM; Szuhai K; Gonçalves MAFV
Nucleic Acids Res; 2022 Jul; 50(13):7761-7782. PubMed ID: 35776127
[TBL] [Abstract][Full Text] [Related]
10. Boosting targeted genome editing using the hei-tag.
Thumberger T; Tavhelidse-Suck T; Gutierrez-Triana JA; Cornean A; Medert R; Welz B; Freichel M; Wittbrodt J
Elife; 2022 Mar; 11():. PubMed ID: 35333175
[TBL] [Abstract][Full Text] [Related]
11. Generation of NERCe003-A-3, a p53 compound heterozygous mutation human embryonic stem cell line, by CRISPR/Cas9 editing.
Li Y; Huang C; Zha L; Kong M; Yang Q; Zhu Y; Peng Y; Ouyang Q; Lu G; Lin G; Zhou D
Stem Cell Res; 2019 Jan; 34():101371. PubMed ID: 30658254
[TBL] [Abstract][Full Text] [Related]
12. The CRISPR/Cas9 system and its applications in crop genome editing.
Bao A; Burritt DJ; Chen H; Zhou X; Cao D; Tran LP
Crit Rev Biotechnol; 2019 May; 39(3):321-336. PubMed ID: 30646772
[TBL] [Abstract][Full Text] [Related]
13. The CRISPR/Cas9 system produces specific and homozygous targeted gene editing in rice in one generation.
Zhang H; Zhang J; Wei P; Zhang B; Gou F; Feng Z; Mao Y; Yang L; Zhang H; Xu N; Zhu JK
Plant Biotechnol J; 2014 Aug; 12(6):797-807. PubMed ID: 24854982
[TBL] [Abstract][Full Text] [Related]
14. Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq.
Turchiano G; Andrieux G; Klermund J; Blattner G; Pennucci V; El Gaz M; Monaco G; Poddar S; Mussolino C; Cornu TI; Boerries M; Cathomen T
Cell Stem Cell; 2021 Jun; 28(6):1136-1147.e5. PubMed ID: 33626327
[TBL] [Abstract][Full Text] [Related]
15. Verification of CRISPR editing and finding transgenic inserts by Xdrop indirect sequence capture followed by short- and long-read sequencing.
Blondal T; Gamba C; Møller Jagd L; Su L; Demirov D; Guo S; Johnston CM; Riising EM; Wu X; Mikkelsen MJ; Szabova L; Mouritzen P
Methods; 2021 Jul; 191():68-77. PubMed ID: 33582298
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Genome Editing and In Vivo Delivery.
Ramirez-Phillips AC; Liu D
AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
Tadić V; Josipović G; Zoldoš V; Vojta A
Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
[TBL] [Abstract][Full Text] [Related]
18. Identifying Signalling Pathways Regulated by GPRC5B in β-Cells by CRISPR-Cas9-Mediated Genome Editing.
Atanes P; Ruz-Maldonado I; Hawkes R; Liu B; Persaud SJ; Amisten S
Cell Physiol Biochem; 2018; 45(2):656-666. PubMed ID: 29408822
[TBL] [Abstract][Full Text] [Related]
19. Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells.
Glaser V; Flugel C; Kath J; Du W; Drosdek V; Franke C; Stein M; Pruß A; Schmueck-Henneresse M; Volk HD; Reinke P; Wagner DL
Genome Biol; 2023 Apr; 24(1):89. PubMed ID: 37095570
[TBL] [Abstract][Full Text] [Related]
20. Lentiviral Vectors for Delivery of Gene-Editing Systems Based on CRISPR/Cas: Current State and Perspectives.
Dong W; Kantor B
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
